Physician profile
Gary K Lefkowitz
NPI 1851335434
$5,306.80
in general payments reported to CMS, 2019-2025
46 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $325 · 2021: $734 · 2022: $963 · 2023: $656 · 2024: $617 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $575.17 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $542.23 | 2019-2025 | Erleada |
| Teleflex LLC | $488.04 | 2021-2025 | Urolift |
| Dendreon Pharmaceuticals LLC | $428.65 | 2019-2025 | Provenge |
| Pfizer INC. | $385.21 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $337.36 | 2023-2025 | Orgovyx, Gemtesa |
| Antares Pharma, INC. | $280.85 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $262.55 | 2019-2025 | |
| Procept Biorobotics Corporation | $204.96 | 2020-2023 | Aquabeam Robotic System |
| Verity Pharmaceuticals INC. | $190.96 | 2023-2025 | Trelstar |
| Abbvie INC. | $127.04 | 2019-2025 | |
| Coloplast Corp | $113.75 | 2019-2025 | |
| Tolmar, INC. | $109.28 | 2023-2025 | Jatenzo |
| Myovant Sciences INC. | $98.65 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $77.72 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Lefkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.